Zealand-CEO: We are creating the biotech-model for the future
Led by Zealand Pharma Danish biotech is now taking things one step further to the next generation of public companies, according to the CEO who dismisses the advice of Big Pharma. A second major biotech company is in agreement.
af LEONORA BECK
From the turn of the millennium a great many biotech companies went public and the stock prices of most of these plummeted rapidly. Among these companies was Genmab, which went public in 2000 with Pharmexa (now Affitech). In 2005 it was Topotarget’s turn and in 2006 Lifecycle Pharma (now Veloxis Pharmaceuticals headed to the stock market.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
